Cytokine release syndrome (CRS) is a form of systemic inflammatory response syndrome (SIRS) that can be triggered by a variety of factors such as infections and certain drugs. It refers to cytokine storm syndromes (CSS) and occurs when large numbers of white blood cells are activated and release inflammatory cytokines, which in turn activate yet more white blood cells. CRS is also an adverse effect of some monoclonal antibody medications, as well as adoptive T-cell therapies. When occurring as a result of a medication, it is also known as an infusion reaction.

Market Analysis and Insights: Global Cytokine Release Syndrome Treatment Market
The global Cytokine Release Syndrome Treatment market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Cytokine Release Syndrome Treatment Scope and Market Size
The global Cytokine Release Syndrome Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Cytokine Release Syndrome Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Oral
Intravenously

Segment by Application
Hospitals
Homecare
Specialty Clinics
Others

The Cytokine Release Syndrome Treatment market is analysed and market size information is provided by regions (countries). Segment by Application, the Cytokine Release Syndrome Treatment market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Roche
Incyte Corporation
Jazz pharmaceuticals
Novartis
CytoSorbents
Swedish Orphan Biovitrum (Sobi)